子分类：
| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 61 | 톨루엔 용매를 사용한 아세토아세트아닐라이드류의 제조방법 | KR1019970031329 | 1997-07-07 | KR1019990009064A | 1999-02-05 | 김홍경; 송원섭; 김만종; 손광훈 |
| 본 발명은 디케텐과 아닐라이드류를 원료로 사용하여 아세토아세트아닐라이드류를 제조하는 방법에 있어서, 톨루엔을 반응용매로 사용하고, 반응물 디케텐(II)과 아닐라이드(III)를 몰비로 1.05~1.10/1.00반응량 투입하여 초산 촉매하에서 0~30℃에서 반응시킴을 특징으로 하는 아세토아세트아닐라이드류의 제조방법에 관한 것이다. | ||||||
| 62 | 폴리우레탄 분해물, 폴리우레탄 및 폴리우레탄 형성 방법 | KR1020110088801 | 2011-09-02 | KR1020120033237A | 2012-04-06 | 호조,후사오 |
| PURPOSE: A polyurethane degraded product is provided to convert primary amine in the polyurethane degraded product to secondary amine, thereby improving the compressive strength of reshaped polyurethane. CONSTITUTION: Polyurethane comprises a structure in chemical formula 1, and glycol degraded product of the polyurethane comprises a compound in chemical formula 2. In chemical formula 1 and 2, R is a functional group in chemical formula 1-a, or a functional group in chemical formula 1-b, R' is a functional group in chemical formula 1-c, n is 0-6, and X and Y is O or COO, respectively. A manufacturing method of a polyurethane degraded product comprises a step of reacting toluene diamine, which is included in the glycol degraded product of polyurethane, and/or methylene dianiline with carboxyl acid anhydride in molecule, or a compound having a hydroxyl group and a carboxyl group. | ||||||
| 63 | 스쿠알렌 합성 효소 억제활성을 갖는 신규 화합물, 그의 제조방법 및 그를 포함하는 조성물 | KR1019970050895 | 1997-10-02 | KR1019990030614A | 1999-05-06 | 안인애; 유영준; 장호진; 노성구; 이영진 |
| 본 발명은 새로운 구조의 스쿠알렌 합성 효소 억제 활성을 갖는 화학식 1로 표시되는 신규 화합물, 그의 제조방법 및 그를 포함하는 조성물에 관한 것으로, 본 발명의 화합물은 체내 콜레스테롤 축적을 촉진하는 효소인 스쿠알렌 합성 효소의 활성을 효과적이고 강력하게 억제하고 합성이 용이하여 고지혈증, 관상동맥심장병, 동맥경화증, 심근경색증 등과 같은 심장순환계 질환의 예방 및 치료에 유용하게 이용될 수 있다.
|
||||||
| 64 | 동시 적하법에 의한 아세토아세트아닐라이드류의 제조방법 | KR1019970031327 | 1997-07-07 | KR1019990009062A | 1999-02-05 | 김홍경; 김홍래; 권성헌; 김만종 |
| 본 발명은 아세토아세트아닐라이드류의 제조방법에 관한 것으로서, 더욱 상세하게는 디케텐과 아닐라이드류를 원료로 사용하여 아세토아세트아닐라이드류를 제조하는 신규한 방법에 있어서, 톨루엔을 반응용매로 사용하고, 반응물 디케텐(II)과 아닐라이드(III)를 몰비로 1.05~1.10/1.00 반응량을 동시 적하 투입하여 0~30℃에서 반응시킴을 특징으로 하는 아세토아세트아닐라이드류의 제조방법에 관한 것이다. | ||||||
| 65 | 페녹시카르복실산 아미드 유도체 및 그것을 함유하는 농업용 살균제 | KR1019930019053 | 1993-09-20 | KR100135496B1 | 1998-04-23 | 사사끼노리오; 이또마사히또; 다게하라쥰; 사와이노부미쓰; 다까야마요시히로 |
| 본 발명은 페녹시카르복실산아미드 유도체 [예를들어 2-(2-시아노-4-2-메틸프로필)-N-(1-메톡시카르보닐-1-디플루오로메틸-2-메틸프로필)프로피온아미드] 및 그것을 함유하는 농업용 살균제, 및 그의 합성중간체를 제공한다. 이 화합물은 페톡시카르복실산 할라이드 유도체와 아미노 화합물과의 반응에 의해 합성할 수 있다. | ||||||
| 66 | OMEGA-AMINOALKYLAMIDES OF (R)-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | EP02744900.8 | 2002-02-25 | EP1366018B1 | 2016-07-06 | ALLEGRETTI, Marcello; BERTINI, Riccardo; BERDINI, Valerio; BIZZARRI, Cinzia; CESTA, Maria, Candida; DI CIOCCIO, Vito; CASELLI, Gianfranco; COLOTTA, Francesco; GANDOLFI, Carmelo |
| 67 | 4-dedimethylamino tetracycline compounds | EP10183340.8 | 2003-01-06 | EP2322501A1 | 2011-05-18 | Nelson, Mark L.; Ohemeng, Kwasi |
The present invention pertains, at least in part, to novel substituted 4-dedimethylamino tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression. |
||||||
| 68 | OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | EP02744900.8 | 2002-02-25 | EP1366018A1 | 2003-12-03 | ALLEGRETTI, Marcello; BERTINI, Riccardo; BERDINI, Valerio; BIZZARRI, Cinzia; CESTA, Maria, Candida; DI CIOCCIO, Vito; CASELLI, Gianfranco; COLOTTA, Francesco; GANDOLFI, Carmelo |
| (R) -2-Arylpropionamide compounds of formula (I) are described. The process for their preparation and pharmaceutical preparations thereof are also described. The 2-Arylpropionamides of the invention are useful in the prevention and treatment of tissue damage due to the exacerbate recruitment of polymorphonuclear leukocytes (Leukocytes PMN) and of monocytes at the inflammatory sites. In particular, the invention relates to the R enantiomers of omega-aminoalkylamides of 2-aryl propionic acids, of formula (I), for use in the inhibition of he chemataxis of neutrophils and monocites induced by the C5a fraction of the complement and by other chemotactic proteins whose biological activity is associated with activation of a 7-TD receptor. Selected compounds of formula (I) are dual inhibitors of both the C5a-induced chemotaxis of nutrophils and monocytes and the IL-8-induced chemotaxis of PMN leukocytes. The compounds of the invention are used in the treatment of psoriasis, ulcerative cholitis, glomerular nephritis, acute respiratory insufficiency, idiopathic fibrosis, rheumatoid arthritis and in the prevention and the treatment of injury caused by ischemia and reperfusion. | ||||||
| 69 | METALLOPROTEINASE INHIBITORS | EP95937128.7 | 1995-11-27 | EP0793641B1 | 1999-04-21 | BECKETT, Raymond, Paul; WHITTAKER, Mark; MILLER, Andrew; MARTIN, Fionna, Mitchell |
| Compounds of general formula (I), principally characterized in that R4 is a polyether group, are water soluble matrix metalloproteinase inhibitors. | ||||||
| 70 | Substituierte Naphthacen-5,12-dione und deren Verwendung | EP89810364.3 | 1989-05-18 | EP0344110A3 | 1990-04-04 | Fischer, Walter, Dr.; Baumann, Marcus, Dr.; Finter, Jürgen, Dr.; Kvita, Vratislav, Dr.; Mayer, Carl W., Dr.; Rembold, Manfred, Dr.; Roth, Martin, Dr. |
Mindestens mit einem organischen Thiorest substituierte Naphthacen-5,12-dione sind sowohl Photoinitiatoren für die Photopolymerisation als auch Sensibilisatoren für die Photodimerisation von ethylenisch ungesättigten Verbindungen. Zusammensetzungen aus solchen Naphthacen-5,12-dionen und ethylenisch ungesättigten Verbindungen eignen sich zur Herstellung von Druckfarben, Lacken, Druckplatten, Resistmaterialien oder als Bildaufzeichnungsmaterial. |
||||||
| 71 | 9-Aminoalkylfluorenes | EP85309313.6 | 1985-12-20 | EP0187509A2 | 1986-07-16 | Lacefield, William Bryant; Simon, Richard Lee |
Fluorenes bearing a 9-aminoalkyl substituent are useful antiarrhythmic agents. |
||||||
| 72 | Methods and compositions for selective and targeted cancer therapy | US14916644 | 2014-09-04 | US09789096B2 | 2017-10-17 | Joseph M. Ready; Deepak Nijhawan; Stephen S. Gonzales; Pano Theodoropoulos |
| Provided herein are methods and compositions for selective and targeted cancer therapy, in particular certain benzothiophenes, benzothiazoles, oxalamides, N-acyl ureas and chromones, and their use in selectively treating certain adenocarcinomas. In some embodiments, the selective toxicity of the compounds may be mediated through SCD1 and/or CYP450 such as CYP4F11. | ||||||
| 73 | Omega-aminoalkylamides of R-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells | US13652199 | 2012-10-15 | US09493402B2 | 2016-11-15 | Marcello Allegretti; Riccardo Bertini; Valerio Berdini; Cinzia Bizzarri; Maria Candida Cesta; Vito Di Cioccio; Gianfranco Caselli; Francesco Colotta; Carmelo Gandolfi |
| (R)-2-Arylpropionamide compounds of formula (I), pharmaceutical preparations of the compounds and a process for making the compounds are described. The 2-Arylpropionamides of the invention are useful in the prevention and treatment of tissue damage due to the exacerbated recruitment of polymorphonuclear leukocytes and monocytes at inflammatory sites. In particular, the invention relates to the R enantiomers of omega-aminoalkylamides of 2-aryl propionic acids, of formula (I), for use as inhibitors of chemotaxis of neutrophils and monocytes induced by the C5a fraction of complement and by other chemotactic proteins whose biological activity is associated with activation of a 7-TD receptor. Selected compounds of formula (I) are dual inhibitors of both the C5a-induced chemotaxis of neutrophils and monocytes and the IL-8-induced chemotaxis of polymorphonuclear leukocytes. | ||||||
| 74 | 4-dedimethylamino tetracycline compounds | US14176923 | 2014-02-10 | US09278911B2 | 2016-03-08 | Mark L. Nelson; Kwasi Ohemeng |
| The present invention pertains, at least in part, to novel substituted 4-dedimethylamino tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression. | ||||||
| 75 | Sulfonyl Compound as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1 | US11658766 | 2005-08-03 | US20080318930A1 | 2008-12-25 | Sherman T. Waddell; James M. Balkovec; Gina M. Santorelli; Aaron H. Leeman; Milana Meletic; Xin Gu |
| Sulfonyl derivatives of structural formula I are selective inhibitors of the 11β-hydroxysteroid dehydrogenase-1. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome or Syndrome X, and other symptoms associated with NIDDM. | ||||||
| 76 | Method of preparing alkylated salicylamides via a dicarboxylate intermediate | US11040612 | 2005-01-19 | US20060084646A1 | 2006-04-20 | Joseph Bernadino; Doris O'Toole; William Bay |
| The present invention relates to a method of preparing an alkylated salicylamide from a protected and activated salicylamide via a dicarboxylated salicylamide intermediate. The present invention also relates to dicarboxylic salicylamide delivery agent compounds for the delivery of active agents. Methods of administration are provided as well. | ||||||
| 77 | Polymorphs of sodium 4-{4-chloro-2-hydroxybenzoyl) amino} butanoate | US10501205 | 2003-01-09 | US20050272639A1 | 2005-12-08 | Satej Bhandarkar; Shingai Majuru; Halina Leuchyk |
| The present invention relates to amorphous and polymorphic forms of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate and their use for facilitating the delivery of active agents, such as insulin, to a target. | ||||||
| 78 | Substituted methyl aryl or heteroaryl amide compounds | US11118497 | 2005-04-29 | US20050267170A1 | 2005-12-01 | Hiroki Koike; Kana Kon-i; Yukari Matsumoto; Kazunari Nakao; Yoshiyuki Okumura; Tatsuya Yamagishi |
| This invention provides a compound of the formula (I): wherein X represents a carbon atom or the like: Y represents imino, or the like: R1 represents an alkyl group having from 1 to 6 carbon atoms or the like: R2 and R3 independently represents a hydrogen atom or the like. These compounds are useful for the treatment of disease conditions mediated by prostaglandin such as pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound. | ||||||
| 79 | Compounds and compositions for delivering active agents | US10168275 | 2002-07-15 | US20030216589A1 | 2003-11-20 | David Gschneidner; Andrea Leone-Bay; Eric Wang; John J. Freeman; Doris C. O'Toole; Lynn Shields |
| Amino acid derivative as carrier compounds and compositions which are useful in the delivery of active agents are provided. The active agents can be a peptide, mucopolysaccharide, carbohydrate, or lipid. Methods of administration, including oral administration, and preparation are provided as well. | ||||||
| 80 | Method for producing n-butyryl-4-amino-3-methyl-methyl benzoate and the novel compound n-(4-bromine-2-methylphenyl)-butanamide | US10239678 | 2002-09-24 | US20030065211A1 | 2003-04-03 | Lars Rodefeld; Thomas Hopfner; Alexander Klausener; Horst Behre |
| According to the invention, N-butyryl-4amino-3-methyl-methyl benzoate is obtained in a particularly advantageous manner by, initially, reacting o-toluidine with butyric acid chloride, by brominating the reaction product and by reacting the bromide obtained therefrom with carbon monoxide and methanol in the presence of a palladium catalyst. The invention also relates to the important novel chemical compound N-(4-bromine-2-methylphenyl)-butanamide. | ||||||
QQ群二维码
意见反馈
意见反馈